Floatz logo

Saponin-Based Immunoadjuvant Obi-821

Fallopian Tube Cancer

Memorial Sloan Kettering Cancer CentermixturePhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Fallopian Tube Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BB

View all 50 →

Same molecule, other indications

Saponin-Based Immunoadjuvant Obi-821 is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
breast cancerDormant
B
Indicative ·
58 / 100
View asset →
fallopian tube cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →